Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756642 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL5757798 | 0.91 | LMNA (0.52) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL7221233 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL5755212 | 0.86 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL5756991 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL5756259 | 0.85 | ALOX15 (0.53) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL5756059 | 0.84 | RXFP1 (0.50) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL5755972 | 0.84 | POLB (0.48) | ALDH1A1HPGDTSHRHTTLMNA | |
| SCHEMBL5759318 | 0.83 | ALOX15 (0.52) | SMN1; SMN2ALDH1A1HPGDTSHRHTT | |
| SCHEMBL5757339 | 0.82 | PKM (0.56) | SMN1; SMN2ALDH1A1HPGDTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1208092-B1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO LTD (KR) | 2006-06-21 | — | — | EP | disclosed |
| US-6548667-B2 | For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-04-15 | — | — | US | disclosed |
| EP-1208092-A4 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO LTD (KR) | 2003-01-02 | — | — | EP | disclosed |
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
| EP-1208092-A1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001077092-A1 | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169314-A1 | Sulfonamide derivative as a matrix metalloproteinase inhibitor | MMP9, MMP3, MMP14 | SMN1; SMN2 654/4885ALDH1A1 311/4885HPGD 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.